Storia in 2 fonti

Biocon stock ticks up as Yesafili Biosimilar clinical data gets published in peer-reviewed journals

Biocon's stock rises 1.22% as clinical data for Yesafili biosimilar is published, marking a key milestone for the company.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

Biocon's stock rises 1.22% as clinical data for Yesafili biosimilar is published, marking a key milestone for the company.

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)